Since TNBCs do not respond to hormonal/HER2 targeted therapies due to lack of target receptors, and since no specific promising therapeutic targets were identified, the only treatment modality available for such “no-option” breast cancer patients is the administration of cytotoxic chemotherapeutic drugs [8,9,12,348,349]. Here, ERBB2 is linked to breast cancer.